化学性质：                                                                                                             

产品描述：                                                                                                            

TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice[1][2][3].

A single injection of TAT-Gap19 TFA (i.v. via the tail vein; 55 mg/kg) produces significant immune signal in the brain 24 h later in 4 months old C57Bl6 male mice[1]. TAT-Gap19 TFA (1 mg/kg/day; an osmotic pump implanted in the peritoneal cavity; Two weeks) shows significantly decreased collagen deposition, as well as lowed amounts of α-SMA-positive cells area in mice subjected to treatment with 100-200 mg thioacetamide (TAA)/kg body weight for eight weeks[2].

[1]. VerÓnica Abudara, et al. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 2014 Oct 21;8:306.

[2]. Sara Crespo Yanguas, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3):817.

[3]. Laura Walrave, et al. Inhibition of astroglial connexin43 hemichannels with TAT-Gap19 exerts anticonvulsant effects in rodents. Glia. 2018 Aug;66(8):1788-1804.

特别提醒：